AnthonyJ.OlszanskiMDRPh

Oncology • Philadelphia, PA

Gastrointestinal Cancer, Hematologic Oncology, Melanoma

Phase 1 early drug development for oncologic indications. Practice focus on GI malignancies/melanoma.

Join to view full profile

Dr. Olszanski is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Olszanski's full profile

Already have an account?

Office
333 Cottman Ave
Medical Staff Office
Philadelphia, PA 19111
Phone+1 215-728-6900

Fax+1 215-214-3229

Education & Training

Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Clinical Pharmacology, 2002 - 2004
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 1999 - 2002
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 1996 - 1999
Rutgers New Jersey Medical SchoolClass of 1996
University of MontanaB.S, Pharmacy, 1985 - 1990

Certifications & Licensure

NH State Medical License 2004 - Present
PA State Medical License 2009 - 2024
VT State Medical License 1998 - 2004
American Board of Internal Medicine Medical Oncology
American Board of Clinical PharmacologyClinical Pharmacology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Accelerating Anticancer Agent Development and Validation American Association for Cancer Research, 2006
Methods in Clinical Cancer Research American Association for Cancer Research, 2003
Molecular Biology in Clinical Oncology American Association for Cancer Research, 2002
Awarded November 2000: PGY 6 stipend Tiffany-Blake Fellowship: Triterpenoid Research, July 2001-June 2002, 2002
Dean’s Letter of Accommodation 1993
Upjohn Research Award: Perfluorochemical Research 1990
Smith, Kline, and French Scholarship 1990
University Science Foundation Scholarship 1989
Burroughs-Wellcome Scholarship 1989
Perfluorocarbon Grant (University Grant Program) 1989
Join now to see all

Clinical Trials

Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma Start of enrollment: 2007 Mar 01
Completed
Phase 1
A Study of of MORAb-004 in Subjects With Solid Tumors Start of enrollment: 2009 Mar 01
Completed
Phase 1
A Safety Study of Oral ZSTK474 in Patients With Cancer Start of enrollment: 2011 Jan 01
Completed
Phase 1
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors Start of enrollment: 2011 Jan 01
Completed
Phase 1
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors Start of enrollment: 2012 Jul 01
Completed
Phase 1
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2013 Jan 18
Active, not recruiting
Phase 2
Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients Start of enrollment: 2013 Apr 01
Completed
Phase 1
Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer Start of enrollment: 2016 Mar 17
Completed
Not Applicable
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) Start of enrollment: 2014 Aug 25
Completed
Phase 2
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Start of enrollment: 2015 Sep 01
Completed
Phase 1
MAGE-A4ᶜ¹º³²T for Multi-Tumor Start of enrollment: 2017 May 15
Active, not recruiting
Phase 1
Phase I Study in Advanced Malignancies With 5-ALA Start of enrollment: 2020 Jul 30
Recruiting
Phase 1
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2022 Apr 14
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
5-aminolevulinic Acid In Advanced Malignancies Start of enrollment: 2020 Jul 30
Recruiting
Phase 1
Roles: Contact, Principal Investigator
A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer Start of enrollment: 2021 Nov 05
Suspended
Phase 1
Roles: Principal Investigator, Contact
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Jul 22
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Aug 17
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors Start of enrollment: 2021 Aug 04
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma Start of enrollment: 2022 Nov 30
Suspended
Early Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Annals of Surgical Oncology Practice Guidelines Series: Adjuvant and Neoadjuvant Therapy for Melanoma.
Jeffrey M Farma, Anthony J Olszanski, Jane L Messina, Vernon K Sondak
Annals of Surgical Oncology. 2024-11-04
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024.
John A Thompson, Bryan J Schneider, Julie Brahmer, Mohammad Abu Zaid, Amaka Achufusi
Journal of the National Comprehensive Cancer Network. 2024-11-01
5 citations
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024.
Susan M Swetter, Douglas Johnson, Mark R Albertini, Christopher A Barker, Sarah Bateni
Journal of the National Comprehensive Cancer Network. 2024-07-01

Journal Articles

Phase I dose-escalation study of LCL161, an oral IAP inhibitor, in patients with advanced solid tumors.
Infante JR, Dees EC, Olszanski AJ, JCO
Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: A Phase II trial.
Slingluff CL, Petroni GR, Molhoek KR, Olszanski AJ, CCR
Phase I study of axitinib combined with paclitaxel, docetaxel, or capecitabine in patients with advanced solid tumors.
Martin LP, Kozloff MF, Herbst RS et al. and Olszanski AJ, British Journal of Cancer, 107; 1268-1276
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours.
Kozloff MF, Martin LP, Krzakowski M et al. and Olszanski AJ, British Journal of Cancer, 107; 1277-1285
Phase Ib study of CP-868,596, a PDGFR inhibitor, in combination with docetaxel with or without axitinib, a VEGFR inhibitor.
Michael MM, Vlahovic G, Khamly K, et al. and Olszanski AJ, British Journal of Cancer, 103(10); 1554-61
Does the order of factors affect the product? Lessons learned from the TORCH trial.
Skarbnick, AP, Olszanski AJ, Transl Lung Cancer Res, 2 (1); 50-54
A phase 1 evaluation of vandetanib plus paclitaxel, carboplatin, 5-fluorouracil, and XRT induction therapy followed by surgery for previously untreated locally advan...
Astsaturov IA, et al and Olszanski, AJ, ASCO (2012) Abstract 74
Join now to see all

Abstracts/Posters

Phase 1b study of oral CP-868,596, a highly specific PDGFR inhibitor, in combination with docetaxel.
Michael M, et al. and Olszanski AJ, ACR/NCI/EORTC (2007) Abstract A148
Protection of Cardiac Contractility from Hypoxia by a Perfluorocarbon Emulsion.
Olszanski T and Eyer CL, Proc. Mont. Acad. Sci. 49:171-176 (1989)
Perfluorochemical Applications.
Olszanski AJ, Clerks Comments, University of Montana, School of Pharmacy. (1990)
Effect of perfluorocarbon emulsions on contractility of oxygen-deprived guinea pig atria.
Olszanski T, and Eyer CL, Proc. West. Pharmacol. Soc. 33:149-151 (1990)
Effects of Perfluorodecalin and Perfluorooctylbromide emulsions on peak contractile force and ATP levels in the guinea pig left atrium.
Eyer CL, Olszanski AJ, Smith JR, Anderson AC, and Irem SO, Biomat. Artif. Cells Artif. Org. 19(4):719-729 (1991)
Human hematopoietic colony formation is highly sensitive to the novel synthetic triterpenoid 2 -cyano-3,12-dioxooleana-1,9-dien-28-oic acid.
Olszanski AJ, Lowrey CH, Sporn MB, Suh N, Blood 98(11):119b (2001) Abstract 4128
The Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid (CDDO) Inhibits Proliferation and Induces Apoptosis of Myeloma Cells in a Time and Dose-Depen...
Olszanski AJ, Lowrey CH, Sporn MB, Suh N, Blood 100(11):816a (2002) Abstract 3224
Molt-4 rho(0) cells up regulate stress-induced survival genes in an attempt to overcome the potentially lethal consequence of mitochondrial DNA depletion.
Olszanski AJ, Lewis LD, ASCPT (2004) Abstract
hase 1 and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system (HDDS) for paclitaxel.
Olszanski AJ, ASCO (2004) Abstract 2048
Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of Oral CP-868,596, a Highly Specific PDGFR Inhibitor in Patients with Advanced Cancers.
Lewis N, et al. and Olszanski AJ, ACR/NCI/EORTC (2005) Abstract A228
Dose-escalation Phase 1 study of cabazitaxel (Cbz) + gemcitabine (Gem) in patients (pts) with metastatic or unresectable advanced solid malignancy.
Rixe O, Puzanov I., LoRusso P, et al and Olszanski AJ, ESMO (2012) Abstract 497P
Axitinib (AG-013736) in combination with paclitaxel/carboplatin in patients with advanced solid tumors.
Cohen RB, et al. and Olszanski AJ, AACR/NCI/EORTC (2007) Abstract A157
Pharmacokinetics of an Oral Film-coated Tablet of CP-868,596,a PDGFR Inhibitor, in Patients with Advanced Cancers.
Lewis LD, Reddy NJ et al. and Olszanski AJ, ACR/NCI/EORTC (2008) Abstract 585
Association of diastolic blood pressure (dBP) > 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736).
Rini BI, et al and Olszanski AJ, ASCO (2008) Abstract 3543
Phase I Study of Axitinib (AG-013736) in Combination with Chemotherapy in Patients with Advanced Solid Tumours.
Martin L, et al. and Olszanski AJ, ESMO (2008) Abstract 472P
Axitinib (AG-013736) Combined with Paclitaxel/Carboplatin, Gemcitabine/Cisplatin, or Pemetrexed/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer and Ot...
Kozloff MF, et al. and Olszanski AJ, 13th WCLC (2009) Abstract 7656
First-in-human dose-escalation safety and PK trial of a novel humanized monoclonal CovX body dual inhibitor of angiopoietin 2 and vascular endothelial growth factor.
Mendelson DS, et al. and Olszanski AJ, ASCO (2011) Abstract 3055
Phase 1 and pharmacokinetic (PK)/pharmacodynamic (PD) study of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.
Faivre S, Olszanski AJ, ASCO (2012) Abstract 2554
Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: Phase II trial with correlative studies.
Slingluff CL, et al and Olszanski AJ, ASCO (2012) Abstract 8530
Join now to see all

Press Mentions

Could a Blood Test Effectively Screen for Cancers?September 20th, 2022
New Cell Therapy Outperforms Immunotherapy in MelanomaSeptember 11th, 2022
More False Than True PositivesSeptember 11th, 2022
Join now to see all

Grant Support

Cancer Genome Institute Clinical Research Pilot GrantFox Chase Cancer Center2013–Present

Committees

Chair, Pharmacy & Therapeutics Committee, FCCC 2012 - Present
Senior Medical Advisor, FCCC Cancer Genome Institute 2012 - Present
Chair, FCCC Genomic Advisory Board 2012 - Present
Member, Data Safety Monitoring Board, FCCC 2012 - Present
Member, NCCN Investigator Steering Committee 2012 - Present
Chair, American Board of Clinical Pharmacology, Credentials Committee 2011 - Present
Member, National Comprehensive Cancer Network, Melanoma Panel 2010 - Present
Member, Research Reivew Committee, FCCC 2009 - Present